TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02813525

Intervention type: OTHER
Intervention: ISI index on Doppler systolic flow in the aortic isthmus
Description: Measure of the ISI index on Doppler systolic flow in the aortic isthmus in the follow-up by ultrasound of the fetus

Intervention type: OTHER
Intervention: ISI index on Doppler systolic flow in the aortic isthmus
Description: Measure of the ISI index on Doppler systolic flow in the aortic isthmus in the follow-up by ultrasound of the fetus
Study: NCT03705572

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lacprodan PL20
Description: Milk protein concentrate that is high in phospholipid content (min 16%).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo milk drink.
Study: NCT00464893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Catumaxomab
Description: 10 µg intraoperative and 4 ascending doses (10, 20, 50 and 150 µg) on day 7, 10, 13 and 16

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: catumaxomab
Description: 10 µg intraoperatively and 4 ascending doses: 10, 20, 50 and 150 µg
Study: NCT01706159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: catridecacog
Description: Catridecacog (recombinant factor XIII, rFXIII) will be administered as intravenous (i.v.) injections (at an approximate rate of 1-2 mL/min) once every second week at a dose of 35 IU/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Placebo will be administered as intravenous (i.v.) injections (at an approximate rate of 1-2 mL/min) once every second week.
Study: NCT01567007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: individual counseling
Description: Consisting of three sessions within a maximum period of 3 months. We conducted a counseling, aimed at increasing physical activity, aiming to raise at least 2000 steps over the first week of monitoring. Furthermore, we discuss the importance of physical activity, such as overcoming barriers to physical activity and targets agreed between the parties. The pedometer is given along with a diary to record the number of steps and returned in the last session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group counseling
Description: The counseling was conducted in groups (10-12 individuals) for 6 sessions at weekly intervals, and two sessions with fortnightly. Each session lasts 60 minutes. The advice is aimed at behavioral changes using the following approaches: advantages and disadvantages of behavior change, how to overcome barriers to physical activity, self-monitoring of physical activity by using the pedometer and setting goals (number of steps / day) in the short term and what to do in case of relapse (not accomplish what was represented) besides livings practices. As the GII and the goal is to raise at least 2000 steps daily on average, with the main focus physical activity in leisure time and transport
Study: NCT04381325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB0254 Injection
Description: An intravenous infusion with concentration from 4 mg/kg to 16 mg/kg every 2 weeks (Q2W).~An intravenous infusion with concentration 20 mg/kg every 3 weeks (Q3W).
Study: NCT03874897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: First-line systemic therapy according to physician's choice
Study: NCT04875650

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraction of Mandibular Molar using Physics Forceps
Description: Extraction of mandibular molars using physics forceps
Study: NCT03886233

Intervention type: DRUG
Intervention: Corticosteroid Series
Description: immunosuppressives are divided into alkylating agents (cyclophosphamide and chlorambucil), antimetabolites (methotrexate, azathioprine, and Mycophenolate Mofetil), and calcineurin inhibitors (cyclosporine, tacrolimus and sirolimus) Biological anti-inflammatory agents (for exapmle antagonists of tumor necrosis factor alpha like Infliximab and adalimumab).
Study: NCT01230801

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMN 701
Description: GILT-tagged recombinant human GAA
Study: NCT03578029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGN-137
Description: It will be applied topically to the appropriate wound once a day for up to 84 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It will be applied topically to the appropriate wound once a day for up to 84 days.
Study: NCT01494480

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stem cell transplantation
Description: after stem cell prepared, the patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments. The patient would have to be in the bed at least 6 hours and removed the pillow.
Study: NCT04875650

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Extraction of Mandibular Molar using Conventional Forceps
Description: Extraction of mandibular molars using conventional forceps
Study: NCT01180816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Super-Selective Intraarterial Intracranial Infusion of Temozolomide
Description: A single dose of Intraarterial Mannitol to open the blood brain barrier followed by Intra-arterial Temozolomide single dose (starting at 75mg/m2 and up to 250mg/m2)
Study: NCT02288559

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham injection will be administered as a matching intravitreal injection of lampalizumab.
Study: NCT03036345

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual-monitoring
Description: Monitored using both INVOS and FORE-SIGHT monitors.
Study: NCT02288559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lampalizumab
Description: 10 mg dose of lampalizumab administered intravitreally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lampalizumab
Description: 10 mg dose of lampalizumab administered intravitreally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lampalizumab
Description: 10 mg dose of lampalizumab administered intravitreally
Study: NCT01757561

Intervention type: PROCEDURE
Intervention: propofol
Description: use total intravenous anesthesia with propofol

Intervention type: PROCEDURE
Intervention: propofol
Description: use total intravenous anesthesia with propofol

Intervention type: PROCEDURE
Intervention: sevoflurane
Description: use inhalation anesthesia with sevoflurane

Intervention type: PROCEDURE
Intervention: sevoflurane
Description: use inhalation anesthesia with sevoflurane
Study: NCT03350893

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Emulsion base with probiotics
Description: Water、Polyglyceryl-3/ Methylglucose Distearate、Triethyl Hexanoin、Macadamia Ternifolia Seed Oil、Propanediol、PEG/PPG/Polybutylene Glycol-8/5/3 Glycerin、Cetyl Alcohol、Myristyl Myristate、Glycerin、Glycosyl Trehalose/Hydrogenated Starch Hydrolysate、Rice Ferment Filtrate(Sake)、Saccharomyces/Daylily Flower Ferment Filtrate、Bis-PEG/PPG-20/5 PEG/PPG-20/5Dimethicone、Methoxy PEG/PPG-25/4 Dimethicone、Caprylic/Capric Triglyceride、Sodium Polyacrylate、Phenoxyethanol、o-Cymen-5-ol、Xanthan Gum、Potassium Hydroxide, Heat-killed L. plantarum powders (1x10\^9 cells/ g-cream)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Emulsion base
Description: Water、Polyglyceryl-3/ Methylglucose Distearate、Triethyl Hexanoin、Macadamia Ternifolia Seed Oil、Propanediol、PEG/PPG/Polybutylene Glycol-8/5/3 Glycerin、Cetyl Alcohol、Myristyl Myristate、Glycerin、Glycosyl Trehalose/Hydrogenated Starch Hydrolysate、Rice Ferment Filtrate(Sake)、Saccharomyces/Daylily Flower Ferment Filtrate、Bis-PEG/PPG-20/5 PEG/PPG-20/5Dimethicone、Methoxy PEG/PPG-25/4 Dimethicone、Caprylic/Capric Triglyceride、Sodium Polyacrylate、Phenoxyethanol、o-Cymen-5-ol、Xanthan Gum、Potassium Hydroxide
Study: NCT01057550

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous fascial sling
Description: Retropubic bottom up mid urethral sling made using autologous rectus sheath fascia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TVT
Description: Standard TVT as described by Ulmsten 1996

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pelvicol
Description: retropubic mid urethral sling made from Pelvicol
Study: NCT04025307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bacTRL-IL-12
Description: bacTRL-IL-12 is a live, genetically modified Bifidobacterium longum (B longum), for administration via IV infusion. The probiotic bacteria selectively colonize solid tumour tissues and are engineered to deliver genetic material encoding the pro-inflammatory transgene Interleukin-12 (IL-12). Plasmid DNA encoding the IL-12 transgene is delivered to the patient's cells within the tumor microenvironment, whereupon IL-12 is expressed to stimulate local and systemic anti-tumour immune responses.
Study: NCT01942291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin
Description: The study was randomized, double-blind, controlled, using a 2-way crossover design with both treatment periods and washout time lasting 7 days. Subjects were allocated by simple randomization to extended-release niacin 1g/day alone (ERN, Metri, Libbs Farmacêutica, São Paulo, Brazil) or niacin associated with LRPT 1g/20mg (ERN/LRPT, Cordaptive, Merck, São Paulo, Brazil).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin
Description: The study was randomized, double-blind, controlled, using a 2-way crossover design with both treatment periods and washout time lasting 7 days. Subjects were allocated by simple randomization to extended-release niacin 1g/day alone (ERN, Metri, Libbs Farmacêutica, São Paulo, Brazil) or niacin associated with LRPT 1g/20mg (ERN/LRPT, Cordaptive, Merck, São Paulo, Brazil).
Study: NCT06215599

Intervention type: OTHER
Intervention: Survey
Description: The survey consisted of 14 questions that thoroughly examined the participants' knowledge levels of these conditions, as well as their indication preferences related to BAHIs.

Intervention type: OTHER
Intervention: Survey
Description: The survey consisted of 14 questions that thoroughly examined the participants' knowledge levels of these conditions, as well as their indication preferences related to BAHIs.
Study: NCT01848002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: catridecacog
Description: For 5 consecutive days, one daily dose of rFXIII was administered intravenously (IV) to eight subjects in each dose group (10 or 25 U/kg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: For 5 consecutive days, one daily dose of placebo was administered intravenously (IV) to two subjects in each dose group (10 or 25 U/kg).
Study: NCT03043300

Intervention type: OTHER
Intervention: Short-Term Post-Travel Questionnaire
Description: The short-term post-travel questionnaire is a 19 item instrument collecting information about dates and locations of travel, food and beverages consumed while traveling, and illnesses during or following traveling.~This questionnaire will be administered verbally by the study team and completed 2 weeks after returning to the United States from travel.

Intervention type: OTHER
Intervention: Short-Term Post-Travel Stool Specimen Collection
Description: The short-term post-travel stool specimen collection will occur 2 weeks after returning to the United States from travel.~The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention.
Study: NCT01811173

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-physician comprehensive care
Description: Components of the intervention include:~1. Complete assessment of the patient's and family's needs conducted by the nurse.~2. Comprehensive treatment program developed by the nurse and in consultation with the primary care physician.~3. Multimorbid care plan integrating all care aspects.~4. Action Plan for patients, supporting self management~5. Proactive monitoring according to the plan.
Study: NCT02536066

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postprandial physical activity
Description: Adding a minimum of 30 minutes of physical activity starting maximum 30 minutes after the last meal daily
Study: NCT04022408

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liquid based cytology
Description: Liquid based cytology

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cytology
Description: Conventional cytology
Study: NCT01303887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375mg/m2 IV day 1,repeated every 21 days for 8 cycles. All patients who have achieved a CR or PR to induction therapy will receive rituximab maintenance (375mg/m2 every 2 months for 2 years).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide 250mg/m2 PO day 1-3, repeated every 21 days for 4 (R-FC) or 8 cycles (R-CVP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 250mg/m2 PO day 1-3, repeated every 21 days for 4 (R-FC) or 8 cycles (R-CVP)
Study: NCT04075422

Intervention type: DRUG
Intervention: Bezlotoxumab Injection [Zinplava]
Description: Treatment with bezlotoxumad according to the routine clinical practices
Study: NCT01567007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic training
Description: The fitness program is held two times per week with individuals and groups with three sessions lasts for 40 minutes performed on a treadmill.
Study: NCT01579071

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CO2 or room air insufflation during ESD for gastric tumor
Description: CO2 insufflation group : CO2 will be insufflated via the endoscope during procedure as needed, Room air insufflation group : Room air will be insufflated via the endoscope during procedure as needed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CO2 or room air insufflation during ESD for gastric tumor
Description: CO2 insufflation group : CO2 will be insufflated via the endoscope during procedure as needed, Room air insufflation group : Room air will be insufflated via the endoscope during procedure as needed
Study: NCT00336882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol at a dose of 1 mg/kg/hour with a dose increase of 1 mg/kg until therapeutic effect (with a maximum dose of 5 mg/kg/hour)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam at a dose of 0,03 mg/kg/hour with dose increasing of 0,02 mg/kg/hour until therapeutic effect.
Study: NCT03742622

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CON . control condition without exercise / rest condition
Description: CON . Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EX. Condition with an acute exercise set in the middle of the morning
Description: EX. Condition with an acute exercise set in the middle of the morning The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) in the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EX+R. condition with an acute exercise set in the morning and followed by a energy replacement snack
Description: EX+R. condition with an acute exercise set in the morning and followed by a energy replacement snack The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) in the morning followed by a snack that will cover the whole exercise-induced energy expenditure. They will then receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
Study: NCT02563119

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric Bypass or Sleeve gastrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric Bypass or Sleeve gastrectomy
Study: NCT01589341

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03584074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 75mg
Description: Orally taken twice daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celebrex 200Mg Capsule
Description: Orally taken once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celebrex 200Mg Capsule
Description: Orally taken once daily for 8 weeks
Study: NCT04015583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exergaming group
Description: Exergame is 'exercise + game'. Treadmill exercise is traiditional aerobic exercise
Study: NCT01179802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strenuous Endurance exercise
Description: Jungfraumarathon: Mountain-Marathon with a length of 42km and a altitude-difference of approximately 1830meters.
Study: NCT01709006

Intervention type: RADIATION
Group type: OTHER
Intervention: Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions
Description: Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions
Study: NCT01303887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Vincristine 1.4mg/m2 IV day 1,repeated every 21 days for 8 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone 40mg/m2 PO day 1-5, repeated every 21 days for 8 cycles.
Study: NCT02548299

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Education
Description: Nutrition classes will be led by a registered dietician.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Education
Description: Nutrition classes will be led by a registered dietician.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Education
Description: Nutrition classes will be led by a registered dietician.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cooking Lecture

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cooking Demo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hands-on Cooking
Study: NCT03152734

Intervention type: PROCEDURE
Intervention: Surgical or non-surgical intervention
Description: Each kind of surgical or non-surgical intervention with anesthesia applied by an anesthetist
Study: NCT02548299

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Coaching

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Coaching

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Coaching
Study: NCT01124942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MGuard net protective coronary stent
Description: It is a new closed-cell design stent concept. with an ultra-thin flexible polyethylene terephthalate (or Dacron) mesh sleeve, anchored to the external surface of the struts. This net (string diameter 10-22 μm) minimally affects stents' trackability and deliverability. During stent deployment, the net stretches and slides over the expanding stent struts, trapping the thromboembolic debris underneath the fiber net.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare-metal stent and manual thrombectomy device
Description: Manual thrombectomy device as an adjunctive strategy for conventional stenting with a bare-metal stent
Study: NCT03347396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIVV009
Description: Sutimlimab was administered as intravenous (IV) infusion.
Study: NCT01847534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplemental PN
Study: NCT03043300

Intervention type: OTHER
Intervention: Long-Term Post-Travel Questionnaire
Description: The long-term post-travel questionnaire is a 16 item instrument collecting information about illnesses since last study visit, dietary habits since last study visit, and any traveling since the last visit.~This questionnaire will be administered verbally by the study team and completed 14 weeks after returning to the United States from travel.

Intervention type: OTHER
Intervention: Long-Term Post-Travel Stool Specimen Collection
Description: The short-term post-travel stool specimen collection will occur 14 weeks after returning to the United States from travel.~The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention.
Study: NCT00675844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elvucitabine
Description: 10 milligrams (mg) elvucitabine daily as part of an ART regimen
Study: NCT01303887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 40mg/m2 PO day 1-3,repeated every 21 days for 4 cycles
Study: NCT02913547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silk'n HST
Description: Treatment with Silk'n HST on the periorbital area as instructed in the user's manual
Study: NCT04098029

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low HLA group CBU infusion
Description: CB-MNC (Cord Blood Mononuclear Cells) infusion from different donors. One dose consists of 2-15х10\^7 cells per 1 kg of patient weight for each infusion. The protocol includes 2 infusions with an interval of 6-x months. HLA compatibility of CB is 3 or fewer by A, B, DRB1 loci.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High HLA group CBU infusion
Description: CB-MNC (Cord Blood Mononuclear Cells) infusion from different donors. One dose consists of 2-15х10\^7 cells per 1 kg of patient weight for each infusion. The protocol includes 2 infusions with an interval of 6-x months. HLA compatibility of CB is 4 or more by A, B, DRB1 loci.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard therapy
Description: The standard therapy can include drugs, special psychology training, etc.
Study: NCT06220227

Intervention type: PROCEDURE
Intervention: vitrification and thawing procedures
Description: Vitrification and thawing are crucial steps in infertility treatment. Vitrification solutions are aqueous cryoprotectant solutions that undergo solidification (and not freezing) when cooled at high rates to very low temperatures, thanks to an increase in viscosity.~Thawing consists in remove the cryoprotectants, warm and dilute the blastocyst.

Intervention type: PROCEDURE
Intervention: vitrification and thawing procedures
Description: Vitrification and thawing are crucial steps in infertility treatment. Vitrification solutions are aqueous cryoprotectant solutions that undergo solidification (and not freezing) when cooled at high rates to very low temperatures, thanks to an increase in viscosity.~Thawing consists in remove the cryoprotectants, warm and dilute the blastocyst.